TG and neoplasm: If a post-surgical thyroglobulin level is low in an intermediate–high-risk patient, the clinician will have to decide whether the genomics of the tumor are such that the tumor is a low thyroglobulin producer and therefore unlikely to respond to RAI (No RAI), whether all disease has been successfully resected and RAI would be used for ablative purposes to follow thyroglobulin levels upon surveillance, or whether microscopic disease is suspected and therefore an adjuvant dose of RAI is indicated (Table 1).